Wells Fargo gave a Buy rating on MannKind Corporation on July 11, 2025.

1 report, 1 independent Updated Jul 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

MannKind Corporation Wells Fargo

Keep exploring

Part of

MannKind Corporation focused on the U.S. market for pharmaceuticals in July 2025. All 1 developments

The entities involved

MannKind Corporation
biopharmaceutical company
- MannKind Corporation stock trades on the Nasdaq electronic exchange, with market data reported by MarketBeat.Thu 18:09
Wells Fargo
American multinational banking and financial services company
- Wells Fargo upgraded Sweetgreen stock to overweight from equal weight on September 28, 2026.Mon 16:33
- Capital Research Global Investors acquired and increased its stake in Wells Fargo stock on June 19, 2026.Mon 16:28

Related events

Coverage

Newest first; wire copies grouped

Jul 11Insider MonkeyWells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 8, Wells Fargo anal